Stellaromics Launches Revolutionary 3D Spatial Transcriptomics System at University of Glasgow

Stellaromics Unveils Pyxa™ at University of Glasgow

Stellaromics, a leader in 3D spatial biology, has officially launched its groundbreaking Pyxa™ 3D spatial transcriptomics system at the University of Glasgow. Located in the laboratory of Dr. Nigel Jamieson, a prominent figure in the field of Hepatobiliary and Pancreatic Surgery, this installation represents a significant turning point for external beta testing in premier research applications.

Dr. Jamieson and his team at the Jamieson Spatial Laboratory are poised to leverage the capabilities of the Pyxa system to analyze the intricate cellular structures associated with various types of cancer, particularly focusing on the tumor microenvironment. “This technology has the potential to revolutionize our understanding of cancer's complex interactions with its surroundings. By integrating spatial context with single-cell precision, we can unveil how tumors invade adjacent tissues, blood vessels, and nerves,” Dr. Jamieson stated.

The innovative Pyxa system aims to dissect the cellular landscapes within tumors and overcome the traditional limitations found in conventional 2D imaging methods. With its capacity to deliver high-resolution, multiplexed 3D spatial transcriptomics in tissue sections up to 100 micrometers thick, Pyxa preserves native tissue architecture and addresses issues where cellular misassignments can occur. This is particularly crucial in the context of aggressive cancers like glioblastoma, pancreatic cancer, and colorectal cancer.

Dr. Jamieson emphasized, “With the Pyxa technology, we are excited to map the physical organization of tissue interfaces and obtain precise single-cell phenotypes in three-dimensional space. This approach will help address persistent challenges in capturing tissue morphology while avoiding cellular misassignments.”

Beyond Dr. Jamieson’s ongoing research, the laboratory functions as a spatial biology core facility, pledging to collaborate widely across multiple sample types in order to showcase the Pyxa system's unique capabilities and transformative potential in 3D spatial transcriptomics.

“Implementing this robust tool in more patient-derived samples and models will enhance our understanding of cancer's dynamic nature,” he added.

Stellaromics aims to catalyze a shift in biological research by enabling scientists to look beyond flat, 2D snapshots. Their approach will provide a clearer picture of the three-dimensional complexity inherent to tissue biology.

Todd Dickinson, the CEO of Stellaromics, heralded this installation as a landmark endeavor. “Establishing the first external Pyxa system is a crucial leap toward making true 3D spatial biology available to the global research community. We believe that Dr. Jamieson’s team, known for their innovative work in spatial biology, is the ideal partner to validate the many applications of Pyxa across multiple disease domains. This cooperation supports our mission of commercializing a system that can deliver unprecedented insights into complex tissue architectures, employing the tumor microenvironment as a starting point.”

Looking ahead, Stellaromics plans to roll out additional installations of the Pyxa system at reputable academic and research institutions in the upcoming months, further solidifying its role as a pioneer in spatial biology. Moreover, the company is set to demonstrate the Pyxa platform and its innovative applications at the American Society of Human Genetics (ASHG) Annual Meeting, taking place from October 14 to 18, 2025, in Boston.

Stellaromics, based in Boston, Massachusetts, is committed to developing cutting-edge methodologies that illuminate the complexities of biological systems for groundbreaking discoveries that can ultimately enhance human health. Their mission is to empower researchers with advanced tools that unveil the intricate nature of biological frameworks.

For further insights or inquiries regarding Pyxa™, interested parties are encouraged to contact Kristen White, Co-Founder and Partner at Oak Street Communications.